Protecting Health Care and Lowering Costs Act of 2025

The 'Protecting Health Care and Lowering Costs Act of 2025' (HR4849) was introduced in the House on August 1, 2025, and subsequently referred to the Committees on Ways and Means and Energy and Commerce. This bill, sponsored by Rep. Gray [D-CA-13] with 140 cosponsors, seeks to make permanent the temporary provisions that expand eligibility for and increase the amount of the premium tax credit. Currently, the maximum income limit for these credits is eliminated until 2025, and this bill proposes to permanently remove the 400% of FPL income cap, thereby expanding the pool of eligible individuals. The bill does not specify a direct funding amount but rather modifies the tax code to increase the availability of premium tax credits. This mechanism acts as an incentive for individuals to purchase health insurance through exchanges, effectively increasing the customer base for health insurance providers. The financial impact on the government would be through increased tax expenditures rather than direct appropriations to companies. Structural winners under this legislation are health insurance providers, as a larger insured population directly translates to increased premium revenue and a more stable risk pool. Companies like UnitedHealth Group ($UNH), Humana Inc. ($HUM), Molina Healthcare, Inc. ($MOH), and CVS Health Corporation ($CVS) (through its Aetna segment) are positioned to benefit. The market data provided shows significant positive movement for these tickers over the past 7 and 30 days. $UNH is up +4.12% in 7 days and +42.11% in 30 days, $HUM is up +7.13% in 7 days and +37.74% in 30 days, $MOH is up +23.62% in 7 days and +41.12% in 30 days, and $CVS is up +6.15% in 7 days and +15.77% in 30 days. These movements suggest that the market is already pricing in the potential benefits of such legislation. The bill is currently in the early stages of the legislative process, having been referred to two committees. The presence of 140 cosponsors indicates significant support within the House. Related bills, such as S2556, also titled 'Protecting Health Care and Lowering Costs Act,' suggest a coordinated effort across both chambers, which could increase the probability of eventual passage. However, the bill must still pass through committee review, floor votes in both the House and Senate, and ultimately receive presidential assent. The Executive Order on 'Accelerating Medical Treatments for Serious Mental Illness' is not directly relevant to this bill, as HR4849 focuses on health insurance affordability rather than specific medical treatments or regulatory pathways for pharmaceuticals.